XML 43 R31.htm IDEA: XBRL DOCUMENT
v3.22.4

Concentrations of Credit Risk and Current Expected Credit Losses (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Risks and Uncertainties [Abstract] |
Schedule of concentration of credit risk related to specialty pharmacy customers | The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:
| Percentage of Total Net Product Revenues for the Years Ended, December 31,
| 2022 |  | 2021 |  | 2020
Customer A | 19 | % |  | 18 | % |  | 20 | %
Customer B | 11 | % |  | 12 | % |  | 13 | %
Customer C | 18 | % |  | 18 | % |  | 17 | %
Customer D | 5 | % |  | 9 | % |  | 11 | %
Customer E | 10 | % |  | 11 | % |  | 10 | %
Customer F | 14 | % |  | 8 | % |  | 5 | %

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the specialty pharmaceutical customers. + References No definition available. + Details
Name: | incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock
Namespace Prefix: | incy_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration